Latest Updates

Cancer Research News & Insights

Evidence-based reporting on oncology breakthroughs, prevention research, and treatment advances — written for patients, families, and caregivers.

Featured Article
Treatment Breakthrough August 25, 2026 11 min read

Triple-Negative Breast Cancer Was the Diagnosis Women Feared Most. A New Drug Is Changing That.

Triple-negative breast cancer has no estrogen receptors, no progesterone receptors, and no HER2 amplification — the three main targets used to treat other breast cancers. For decades, chemotherapy was the only systemic option, and outcomes for high-risk early disease were poor. The KEYNOTE-522 trial, published in the New England Journal of Medicine in 2022, changed that picture: pembrolizumab plus chemotherapy improved 3-year event-free survival from 76.8% to 84.5% and is now the standard of care worldwide. Here is the full story, in plain English.

Read full article

All Articles

9 articles
Treatment Breakthrough August 25, 2026

Triple-Negative Breast Cancer Was the Diagnosis Women Feared Most. A New Drug Is Changing That.

Triple-negative breast cancer has no estrogen receptors, no progesterone receptors, and no HER2 amplification — the three main targets used to treat other breast cancers. For decades, chemotherapy was the only systemic option, and outcomes for high-risk early disease were poor. The KEYNOTE-522 trial, published in the New England Journal of Medicine in 2022, changed that picture: pembrolizumab plus chemotherapy improved 3-year event-free survival from 76.8% to 84.5% and is now the standard of care worldwide. Here is the full story, in plain English.

11 min read Read more
Treatment Breakthrough July 23, 2026

Stage IV Melanoma Was a Death Sentence. Then Immunotherapy Changed Everything.

The CheckMate 067 trial, published in the New England Journal of Medicine, showed that combining two immunotherapy drugs — nivolumab and ipilimumab — produces 7-year survival rates of 43% in patients with advanced melanoma. Before this era, the figure was roughly 5%. Here is the story of the most dramatic turnaround in cancer medicine of the past two decades, and what it means for anyone facing a melanoma diagnosis today.

10 min read Read more
Treatment Breakthrough June 30, 2026

The Radioactive Drug That Chases Prostate Cancer Cells Anywhere in the Body

Lutetium-177 PSMA-617 (Pluvicto) is a new type of cancer drug that uses a prostate-specific protein as a GPS to deliver targeted radiation directly to cancer cells, wherever in the body they have spread. The VISION trial, published in the New England Journal of Medicine, showed it extended survival in men with advanced prostate cancer by nearly four months with fewer side effects than chemotherapy. Here is what the science shows and what it means for patients today.

9 min read Read more
Research & Science May 26, 2026

The Throat Cancer Epidemic Most Americans Don't Know They're at Risk For

HPV-positive oropharyngeal cancer — a cancer of the back of the throat driven by the same virus behind most cervical cancers — has quietly become one of the fastest-rising cancers in the United States, and it now surpasses cervical cancer as the most common HPV-related malignancy. Here is what the research shows about who is at risk, how the treatment has been transformed by immunotherapy, and what you can do today.

9 min read Read more
Treatment Breakthrough May 21, 2026

The Patient's Own Immune Cells, Reprogrammed to Kill Cancer

The CARTITUDE-4 trial showed that a single infusion of cilta-cel (Carvykti), a CAR-T therapy built from each patient's own immune cells, cut the risk of disease progression or death by 74% compared with standard chemotherapy in lenalidomide-refractory multiple myeloma. Published in the New England Journal of Medicine in 2023 and followed by an FDA expanded approval in 2024, the trial is changing when and how this cellular therapy is used.

9 min read Read more
Treatment Breakthrough October 8, 2024

When 'HER2-Negative' Is No Longer the Whole Story

The DESTINY-Breast06 trial showed that trastuzumab deruxtecan (Enhertu) nearly doubled progression-free survival in hormone receptor-positive breast cancer patients with very low HER2 expression — a group previously excluded from this class of treatment. The findings, published in the NEJM in June 2024, could reshape how up to 75% of metastatic breast cancer patients are treated.

9 min read Read more
Treatment Breakthrough April 25, 2026

A Daily Pill That Doubled Survival in Pancreatic Cancer

Phase 3 trial results announced in April 2026 show that daraxonrasib, a once-daily oral pill, extended median survival to 13.2 months in patients with previously treated metastatic pancreatic cancer — nearly double the 6.7 months seen with standard chemotherapy.

7 min read Read more
Personalized guidance

Have questions about a cancer diagnosis?

Our patient navigators stay current with the latest research and can help you understand what new findings mean for your specific situation. Free, confidential, no commitment.

Send a message
Free callback

Talk to a navigator

Leave your details and we’ll call you at your preferred time.